Alshanqeeti Shatha, Bhargava Ashish
Internal Medicine, Ascension St. John Hospital, Detroit, USA.
Infectious Disease, King Saud University, Riyadh, SAU.
Cureus. 2022 Jun 23;14(6):e26239. doi: 10.7759/cureus.26239. eCollection 2022 Jun.
Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is an antiviral that was authorized for emergency use in December 2021 for non-hospitalized symptomatic patients with COVID-19 to prevent progression to severe disease. Relapse of symptoms following a period of improvement after treatment with Paxlovid has been described recently. Data are limited, but the disease course in available case reports is usually mild and requires no additional antiviral treatment. We present the cases of COVID-19 relapse (COVID-19 rebound) in two patients following treatment with Paxlovid.
自2020年新冠病毒病被宣布为大流行以来，已研发出多种疗法来减轻新冠病毒感染症状并防止病情进展。帕罗韦德是一种抗病毒药物，于2021年12月被批准用于非住院的有症状新冠病毒病患者，以防止病情进展为重症。最近有关于帕罗韦德治疗后症状改善一段时间后复发的描述。数据有限，但现有病例报告中的病程通常较轻，无需额外的抗病毒治疗。我们报告了两名接受帕罗韦德治疗后出现新冠病毒病复发（新冠病毒反弹）的病例。
